Tuesday broker round-up UPDATE
29th Jul 2014 09:37
Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation. African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy. Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold
Read moreTuesday tips round-up: Hiscox, Reckitt Benckiser, GlaxoSmithKline
29th Jul 2014 07:56
Insurance outfit Hiscox is one of the most respected names in its sector and for good reason. For the first half of the year the outfit achieved a combined ratio of 82%. That marks a deterioration on the 74.7% seen in the comparable period of the year before but is nevertheless a good result. The co
Read moreLondon close: Traders bide their time ahead of US jobs data
28th Jul 2014 17:26
- BskyB paces gains - Lloyds fined $370m by UK and US authorities - Aberdeen Asset Management sees slight drop in AuM techMARK 2,776.05 -0.83% FTSE 100 6,788.07 -0.05% FTSE 250 15,616.53 -0.48% The Footsie finished the session slightly lower as traders bided their time ahead of a raft of key data
Read moreMonday broker round-up UPDATE
28th Jul 2014 11:06
African Barrick Gold: UBS ups target price from 260p to 290p and maintains a buy recommendation. Deutsche Bank cuts target price from 300p to 280p and reiterates a buy recommendation. Anglo American: UBS downgrades from buy to neutral with a target price of 1700p. Barclays: Nomura cuts target pric
Read moreGlaxoSmithKline may spin off consumer healthcare arm - report
28th Jul 2014 10:16
British drug giant GlaxoSmithKline may spin off its consumer health division as it tries to get to grips with increasing competition for its drugs and Chinese bribery allegations, it was reported on Monday. Glaxo may demerge the business, which includes brands such as Aquafresh toothpaste, Panadol
Read moreLondon open: Stocks in holding pattern ahead of key data
28th Jul 2014 09:24
- GSK break-up possibly on the cards - RyanAir reports doubling of first quarter profits - Aberdeen Asset Management sees slight drop in AuM techMARK 2,794.05 -0.19% FTSE 100 6,800.81 +0.14% FTSE 250 15,661.43 -0.19% The Footsie was trading little changed early on in the session, ahead of what was
Read moreFTSE 100 movers: RBS tops the leaders after surprise H1 profit
25th Jul 2014 15:36
RBS delivered a better-than-expected first half operating performance, but said no one at the 80% taxpayer-owned bank was "complacent about the challenges ahead". The results, which came a week earlier than scheduled, showed operating profit totalled £2.6bn, or £3.3bn excluding restructuring and l
Read moreFriday broker round-up UPDATE
25th Jul 2014 09:29
African Barrick Gold: Investec places both its target price (prev.: 212p) and its sell recommendation under review. Westhouse Securities ups target price from 250p to 285p upgrading from neutral to add. Barclays: Deutsche Bank cuts target price from 300p to 275p staying with its buy recommendation.
Read moreGSK seeks regulatory approval for world's first malaria vaccine
24th Jul 2014 15:59
GlaxoSmithKline (GSK) has applied for regulatory approval for the world's first vaccine against malaria. The UK drugmaker's shot RTS,S has been designed for children in Africa. It is intended exclusively for use outside the European Union, but the European Medicines Agency (EMA) will evaluate the
Read moreThursday broker round-up UPDATE
24th Jul 2014 08:59
Afren: JP Morgan shifts target price from 180p to 188p upgrading from underweight to overweight. Anglo American: Jefferies raises target price from 1550p to 1700p and reiterates a hold recommendation. Antofagasta: Jefferies increases target price from 825p to 1000p upgrading from hold to buy. ARM
Read moreFTSE 100 movers: GlaxoSmithKline shares tank as drugmaker lowers outlook
23rd Jul 2014 14:31
The share price ofGlaxoSmithKline tanked 6% on Wednesday afternoon, leading the fallers on the FTSE 100, as the drugmaker disappointed with a 4% drop in quarterly sales to £5.6bn and lowered its full-year outlook. It now expects to deliver 2014 full-year core earnings per share "broadly similar to l
Read moreSector movers: Weak results, outlook from Glaxo sink pharma stocks
23rd Jul 2014 14:17
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read moreGSK's second quarter revenue hurt by drug rivals
23rd Jul 2014 12:16
- Turnover falls 4% - Competition from generic brands hurts profit - Full-year 2014 guidance cut GlaxoSmithKline (GSK) on Wednesday slashed its 2014 outlook as it reported a 4% fall in second quarter revenue to £5.6bn. The drugmaker, which is in deep water over a bribery scandal in China, said cor
Read moreWednesday preview: GSK results, BoE meeting minutes
22nd Jul 2014 16:00
GlaxoSmithKline (GSK) reports its second quarter interims on Wednesday amid an investigation over a bribery scandal in China. Panmure Gordon said it is "not expecting fireworks" from GSK's results. "In light of our recent downgrade to forecasts due to exchange rate headwinds, we are expecting anoth
Read moreWeek ahead: ARM, Glaxo in focus amid a wave of blue-chip earnings
18th Jul 2014 12:54
After a relatively quiet five sessions in terms of UK corporate earnings, things will pick up a gear next week with a host of blue chips expected to update the market on their recent performances. ARM Holdings, which designs chips used in smartphones and tablets, will be in focus on Tuesday as it r
Read more